News
SciSparc Ltd a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval
Read more...31 December 2024
Duality Biologics announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate
Read more...30 December 2024
YolTech Therapeutics, a clinical-stage in vivo gene editing company, announced that the U.S. Food and Drug Administration.
Read more...Argenx SE a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of Health, Labour and Welfare
Read more...26 December 2024
Axcelead Drug Discovery Partners, Inc. announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc
Read more...24 December 2024
OBI Pharma, Inc. (OBI), a global clinical-stage oncology company focused on developing novel cancer therapies such as antibody-drug conjugates (ADCs) and active immunotherapies (4174. TWO), and GlyT
Read more...Bristol Myers Squibb today announced that the European Commission (EC) has approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
Read more...23 December 2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator
Read more...23 December 2024
AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R)
Read more...21 December 2024
Renovaro Inc. a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions
Read more...